22. The composition according to any one of claims 14 to 21, wherein the CD22 antibody-drug conjugate is anti-CD22-MC-vc-PAB-MMAE.

23. The composition according to any one of claims 14 to 22, wherein the anti-CD22 antibody in said CD22 antibody-drug conjugate is 10F4.v3.

~~24. A method of treatment of patient suffering from cancer by administering an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, in combination with a CD22 antibody-drug conjugate, to a patient in the need of such treatment.~~

~~25. The method according to claim 24, characterized in that said cancer is a CD20 expressing cancer.~~

~~26. The method according to claims 24 to 25 characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.~~

~~27. The method according to claims 24 to 26, characterized in that said anti-CD20 antibody is a humanized B-Ly1 antibody.~~

~~28. The method according to any one of claims 24 to 27, characterized in that said anti-CD20 antibody is obinutuzumab.~~

~~29. The method according to any one of claims 24 to 28, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.~~

~~30. The method according to any one of claims 24 to 29, characterized in that said CD22 antibody in the CD22 antibody-drug conjugate comprises (a) an HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs:9, 10, 19-23, 32 and 33, and (b) at least one, two, three, four, or five HVRs selected from:~~

~~(1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:2;~~

~~(2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:4;~~

~~(3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:6;~~

~~(4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:12; and~~

~~(5) an HVR-L3 comprising an amino acid sequence of SEQ ID NO:14.~~

~~31. The method according to any one of claims 24 to 30, characterized in that said CD22 antibody binds to the same epitope as an antibody selected from ATCC PTA-7621 (10F4.4.1).~~

~~32. The method according to any one of claims 24 to 31, the CD22 antibody-drug conjugate having the formula Ab-(L-D)p, wherein~~

~~(a) Ab is the CD22 antibody of claim 30 or 31;~~

~~(b) L is a linker;~~

~~(c) D is a drug moiety.~~

~~33. The method according to any one of claims 24 to 32, the CD22 antibody-drug conjugate having the formula Ab-(L-D)p, wherein L is selected from 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).~~

~~34. The method according to any one of claims 24 to 33, the CD22 antibody-drug conjugate having the formula Ab-(L-D)p, wherein D is selected from the group consisting of auristatin, dolostantin, DM1, DM3, DM4, MMAE and MMAF.~~

~~35. The method according to any one of claims 24 to 34, wherein the CD22 antibody-drug conjugate is anti-CD22-MC-vc-PAB-MMAE.~~

~~36. The method according to any one of claims 24 to 35, wherein the anti-CD22 antibody in said CD22 antibody-drug conjugate is 10F4.v3.~~

~~37.~~24. Use of an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, for the manufacture of a medicament for the treatment of cancer in combination with a CD22 antibody-drug conjugate.

~~38.~~25. The use according to claim ~~37~~24, characterized in that said cancer is a CD20 expressing cancer.

~~39.~~26. The use according to claims ~~37~~ 24 or ~~38~~25, characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.

~~40.~~27. The use according to any one of claims ~~37~~ 24 to ~~39~~26, characterized in that said anti-CD20 antibody is a humanized B-Ly1 antibody.

~~41.~~28. The use according to any one of claims ~~37~~ 24 to ~~40~~27, characterized in that said anti-CD20 antibody is obinutuzumab.

~~42.~~29. The use according to any one of claims ~~37~~ 24 to ~~41~~28, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.

~~43.~~30. The use according to any one of claims ~~37~~ 24 to ~~42~~29, characterized in that said CD22 antibody in the CD22 antibody-drug conjugate comprises (a) an HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs:9, 10, 19-23, 32 and 33, and (b) at least one, two, three, four, or five HVRs selected from:

(1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:2;

(2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:4;

(3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:6;

(4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:12; and

(5) an HVR-L3 comprising an amino acid sequence of SEQ ID NO:14.

~~44.~~31. The use according to any one of claims ~~37~~ 24 to ~~43~~30, characterized in that said CD22 antibody binds to the same epitope as an antibody selected from ATCC PTA-7621 (10F4.4.1).

~~45.~~32. The use according to any one of claims ~~37~~ 24 to ~~44~~31, the CD22 antibody-drug conjugate having the formula Ab-(L-D)p, wherein

(a) Ab is the CD22 antibody of claim ~~43~~ 30 or ~~44~~31;

(b) L is a linker;

(c) D is a drug moiety.

~~46.~~33. The use according to any one of claims ~~37~~ 24 to ~~45~~32, the CD22 antibody-drug conjugate having the formula Ab-(L-D)p, wherein L is selected from 6-maleimidocaproyl

(MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

~~47.~~34. The use according to any one of claims ~~37~~24 to ~~46~~33, the CD22 antibody-drug conjugate having the formula Ab-(L-D)p, wherein D is selected from the group consisting of auristatin, dolostantin, DM1, DM3, DM4, MMAE and MMAF.

~~48.~~35. The use according to any one of claims ~~37~~24 to ~~47~~34, wherein the CD22 antibody-drug conjugate is anti-CD22-MC-vc-PAB-MMAE.

~~49.~~36. The use according to any one of claims ~~37~~24 to ~~48~~35, wherein the anti-CD22 antibody in said CD22 antibody-drug conjugate is 10F4.v3.

~~50.~~37. The use according to any one of claims ~~37~~24 to ~~49~~36, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.